APRE (aprea.com) Dhuwit awis perusahaan

Logo grafis Aprea Therapeutics (APRE)

Aprea Therapeutics (APRE) oncology developments are independent of economic cycles and seasonality. The primary growth is driven by ATRN-119 inhibitor trials for tumor combat. Optimized component supplies guarantee the continuity of tests. The cash balance visualizes liquidity dynamics, while 0.04 captures the current state of the parameter, allowing for an assessment of capital management efficiency.

APRE - Sisa dhuwit perusahaan Aprea Therapeutics ing rentang 04.07.2022 - 21.11.2026

Rincian metrik keuangan lan pasar Aprea Therapeutics (APRE)

Analisis komprehensif perusahaan:APRE Aprea Therapeutics Inc.
Produk mawa merek Aprea

Developing targeted cancer therapies requires colossal capital expenditures. This indicator tracks the remaining liquid assets, allowing for the calculation of the cash burn rate until the point of break-even. By analyzing current cash reserves on GURU.Markets, an investor assesses the risk of a liquidity shortage. For Aprea Therapeutics (APRE), this reserve is critical for protecting a potential monopoly. A stable cash balance confirms the financial stability of the asset.